This study examines the usefulness of peritoneovenous shunts through a retrospective review of the charts of 16 patients who received this shunt at the University Hospital in Saskatoon up to May 1987. Fourteen shunts were placed for malignant ascites, 1 for alcoholic cirrhosis and 1 for nephrogenic ascites. All patients had symptoms related to abdominal pressure or dyspnea. Diuretics were most frequently used as initial management, and paracentesis was performed to relieve symptoms in all but one patient. However, a trial of sodium restriction was used in only eight patients, and only five of these trials lasted longer than 1 week. Thus, the adequacy of medical management was questionable. The death of one patient was directly attributable to the shunt, and the deaths of four others were suspected to be sequelae of surgery or shunting. Only five shunts were functioning at the time the patient died. In this study, the majority of the patients received little benefit from the peritoneovenous shunt.
Download full-text PDF |
Source |
---|
Dis Colon Rectum
February 2025
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio.
Background: Patients with Crohn's disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer-related outcomes remains unclear.
Objective: To investigate the association between prior exposure to biologic treatment and colorectal cancer-related outcomes in patients with underlying Crohn's disease.
Am J Manag Care
January 2025
RAND, 1776 Main St, Santa Monica, CA 90401. Email:
Objectives: Patient experience surveys are essential to measuring patient-centered care, a key component of health care quality. Low response rates in underserved groups may limit their representation in overall measure performance and hamper efforts to assess health equity. Telephone follow-up improves response rates in many health care settings, yet little recent work has examined this for surveys of Medicare enrollees, including those with Medicare Advantage.
View Article and Find Full Text PDFAm J Manag Care
January 2025
McGovern Medical School at UTHealth Houston, 4513 Teas St, Bellaire, TX 77401.
Objective: To examine the effect of physiologic insulin resensitization (PIR) on the cost of treating patients with diabetes and chronic kidney disease (CKD).
Study Design: The mean 1-year cost of treating 66 Medicare Advantage patients with diabetes and CKD who were receiving PIR was compared with that of treating 1301 Medicare Advantage patients with diabetes and CKD not receiving PIR. Differences in disease severity were compared using mean risk adjustment factor scores.
Am J Manag Care
January 2025
Arine, 595 Market St #2550, San Francisco, CA 94105. Email:
Objective: To assess the effects of a nurse-led personalized care plan on the duration of olaparib therapy among patients with cancer.
Study Design: Cohort study conducted from January 2020 to June 2022.
Methods: Data from an independent specialty pharmacy were used to identify patients 18 years and older with at least 1 olaparib (Lynparza) prescription who were at high risk for olaparib nonadherence as assessed using a pharmacy intake survey.
Am J Manag Care
January 2025
Ascension Borgess Hospital, 345 Naomi St, Plainwell, MI 49080. Email:
Objective: To describe the outcomes of a partnership between a drug plan and pharmacists to switch patients from brand name dipeptidyl-peptidase-4 inhibitors to the generic alogliptin.
Study Design: Single-center, retrospective chart review.
Methods: Clinical pharmacists contacted patients with primary care providers within the health system affiliated with the drug plan to facilitate the switch.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!